JPH06503225A - アンギオジェネシス制御特性を有するヒト蛋白をコードするヌクレオチド配列 - Google Patents
アンギオジェネシス制御特性を有するヒト蛋白をコードするヌクレオチド配列Info
- Publication number
- JPH06503225A JPH06503225A JP3515286A JP51528691A JPH06503225A JP H06503225 A JPH06503225 A JP H06503225A JP 3515286 A JP3515286 A JP 3515286A JP 51528691 A JP51528691 A JP 51528691A JP H06503225 A JPH06503225 A JP H06503225A
- Authority
- JP
- Japan
- Prior art keywords
- protein
- sequence
- nucleotide sequence
- nucleotide
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000033115 angiogenesis Effects 0.000 title claims description 14
- 108091028043 Nucleic acid sequence Proteins 0.000 title claims description 9
- 108090000144 Human Proteins Proteins 0.000 title description 3
- 102000003839 Human Proteins Human genes 0.000 title description 3
- 108090000623 proteins and genes Proteins 0.000 claims description 66
- 102000004169 proteins and genes Human genes 0.000 claims description 58
- 239000002773 nucleotide Substances 0.000 claims description 54
- 125000003729 nucleotide group Chemical group 0.000 claims description 54
- 210000004027 cell Anatomy 0.000 claims description 33
- 239000013598 vector Substances 0.000 claims description 27
- 238000000034 method Methods 0.000 claims description 21
- 150000001413 amino acids Chemical class 0.000 claims description 20
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 19
- 230000001105 regulatory effect Effects 0.000 claims description 12
- 230000000694 effects Effects 0.000 claims description 8
- 238000004519 manufacturing process Methods 0.000 claims description 8
- 239000013612 plasmid Substances 0.000 claims description 8
- 230000000295 complement effect Effects 0.000 claims description 5
- 108020004707 nucleic acids Proteins 0.000 claims description 5
- 102000039446 nucleic acids Human genes 0.000 claims description 5
- 150000007523 nucleic acids Chemical class 0.000 claims description 5
- 230000001580 bacterial effect Effects 0.000 claims description 4
- 230000001413 cellular effect Effects 0.000 claims description 4
- 230000008569 process Effects 0.000 claims description 4
- 230000002588 toxic effect Effects 0.000 claims description 4
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 claims description 3
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 claims description 3
- 239000003550 marker Substances 0.000 claims description 3
- 230000003287 optical effect Effects 0.000 claims description 3
- 238000013518 transcription Methods 0.000 claims description 3
- 230000035897 transcription Effects 0.000 claims description 3
- 241000894006 Bacteria Species 0.000 claims description 2
- 230000002068 genetic effect Effects 0.000 claims description 2
- 239000007788 liquid Substances 0.000 claims description 2
- 230000002934 lysing effect Effects 0.000 claims description 2
- 230000004936 stimulating effect Effects 0.000 claims description 2
- 231100000331 toxic Toxicity 0.000 claims description 2
- 238000013519 translation Methods 0.000 claims description 2
- 230000002491 angiogenic effect Effects 0.000 claims 3
- 108010047956 Nucleosomes Proteins 0.000 claims 2
- 210000001623 nucleosome Anatomy 0.000 claims 2
- 241000588724 Escherichia coli Species 0.000 claims 1
- 108020005091 Replication Origin Proteins 0.000 claims 1
- 230000003115 biocidal effect Effects 0.000 claims 1
- 239000003623 enhancer Substances 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 239000012139 lysis buffer Substances 0.000 claims 1
- 125000000896 monocarboxylic acid group Chemical group 0.000 claims 1
- 210000004940 nucleus Anatomy 0.000 claims 1
- 230000008488 polyadenylation Effects 0.000 claims 1
- 239000002299 complementary DNA Substances 0.000 description 16
- 101001001487 Homo sapiens Phosphatidylinositol-glycan biosynthesis class F protein Proteins 0.000 description 14
- 101000595923 Homo sapiens Placenta growth factor Proteins 0.000 description 14
- 102100035194 Placenta growth factor Human genes 0.000 description 14
- 239000012634 fragment Substances 0.000 description 13
- 239000003102 growth factor Substances 0.000 description 7
- 108020004414 DNA Proteins 0.000 description 5
- 239000002870 angiogenesis inducing agent Substances 0.000 description 5
- 230000001656 angiogenetic effect Effects 0.000 description 5
- 108020004999 messenger RNA Proteins 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 108091026890 Coding region Proteins 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 238000010367 cloning Methods 0.000 description 4
- 238000012217 deletion Methods 0.000 description 4
- 230000037430 deletion Effects 0.000 description 4
- 210000002889 endothelial cell Anatomy 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 238000002955 isolation Methods 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 230000001173 tumoral effect Effects 0.000 description 4
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 3
- 108091023045 Untranslated Region Proteins 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 230000004071 biological effect Effects 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 239000013604 expression vector Substances 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 230000001900 immune effect Effects 0.000 description 3
- 238000003780 insertion Methods 0.000 description 3
- 230000037431 insertion Effects 0.000 description 3
- 239000006166 lysate Substances 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- 238000000636 Northern blotting Methods 0.000 description 2
- 108091034117 Oligonucleotide Proteins 0.000 description 2
- 101150062123 Pigf gene Proteins 0.000 description 2
- 108020004511 Recombinant DNA Proteins 0.000 description 2
- 102000006747 Transforming Growth Factor alpha Human genes 0.000 description 2
- 101800004564 Transforming growth factor alpha Proteins 0.000 description 2
- 208000025865 Ulcer Diseases 0.000 description 2
- 206010052428 Wound Diseases 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 230000001594 aberrant effect Effects 0.000 description 2
- 230000000692 anti-sense effect Effects 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 230000001268 conjugating effect Effects 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 210000003527 eukaryotic cell Anatomy 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 208000027866 inflammatory disease Diseases 0.000 description 2
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 2
- 230000005012 migration Effects 0.000 description 2
- 238000013508 migration Methods 0.000 description 2
- 239000003068 molecular probe Substances 0.000 description 2
- 230000001613 neoplastic effect Effects 0.000 description 2
- 238000000088 particle-induced gamma-ray emission spectroscopy Methods 0.000 description 2
- 229920002401 polyacrylamide Polymers 0.000 description 2
- 239000006041 probiotic Substances 0.000 description 2
- 230000000529 probiotic effect Effects 0.000 description 2
- 235000018291 probiotics Nutrition 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 230000014616 translation Effects 0.000 description 2
- 231100000397 ulcer Toxicity 0.000 description 2
- 210000005166 vasculature Anatomy 0.000 description 2
- 239000002023 wood Substances 0.000 description 2
- NMWKYTGJWUAZPZ-WWHBDHEGSA-N (4S)-4-[[(4R,7S,10S,16S,19S,25S,28S,31R)-31-[[(2S)-2-[[(1R,6R,9S,12S,18S,21S,24S,27S,30S,33S,36S,39S,42R,47R,53S,56S,59S,62S,65S,68S,71S,76S,79S,85S)-47-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-3-methylbutanoyl]amino]-3-methylbutanoyl]amino]-3-hydroxypropanoyl]amino]-3-(1H-imidazol-4-yl)propanoyl]amino]-3-phenylpropanoyl]amino]-4-oxobutanoyl]amino]-3-carboxypropanoyl]amino]-18-(4-aminobutyl)-27,68-bis(3-amino-3-oxopropyl)-36,71,76-tribenzyl-39-(3-carbamimidamidopropyl)-24-(2-carboxyethyl)-21,56-bis(carboxymethyl)-65,85-bis[(1R)-1-hydroxyethyl]-59-(hydroxymethyl)-62,79-bis(1H-imidazol-4-ylmethyl)-9-methyl-33-(2-methylpropyl)-8,11,17,20,23,26,29,32,35,38,41,48,54,57,60,63,66,69,72,74,77,80,83,86-tetracosaoxo-30-propan-2-yl-3,4,44,45-tetrathia-7,10,16,19,22,25,28,31,34,37,40,49,55,58,61,64,67,70,73,75,78,81,84,87-tetracosazatetracyclo[40.31.14.012,16.049,53]heptaoctacontane-6-carbonyl]amino]-3-methylbutanoyl]amino]-7-(3-carbamimidamidopropyl)-25-(hydroxymethyl)-19-[(4-hydroxyphenyl)methyl]-28-(1H-imidazol-4-ylmethyl)-10-methyl-6,9,12,15,18,21,24,27,30-nonaoxo-16-propan-2-yl-1,2-dithia-5,8,11,14,17,20,23,26,29-nonazacyclodotriacontane-4-carbonyl]amino]-5-[[(2S)-1-[[(2S)-1-[[(2S)-3-carboxy-1-[[(2S)-1-[[(2S)-1-[[(1S)-1-carboxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-(1H-imidazol-4-yl)-1-oxopropan-2-yl]amino]-5-oxopentanoic acid Chemical compound CC(C)C[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H]1CSSC[C@H](NC(=O)[C@@H](NC(=O)[C@@H]2CSSC[C@@H]3NC(=O)[C@H](Cc4ccccc4)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](Cc4c[nH]cn4)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H]4CCCN4C(=O)[C@H](CSSC[C@H](NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](Cc4c[nH]cn4)NC(=O)[C@H](Cc4ccccc4)NC3=O)[C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc3ccccc3)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N3CCC[C@H]3C(=O)N[C@@H](C)C(=O)N2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](Cc2c[nH]cn2)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)C(C)C)[C@@H](C)O)C(C)C)C(=O)N[C@@H](Cc2c[nH]cn2)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](Cc2ccc(O)cc2)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1)C(=O)N[C@@H](C)C(O)=O NMWKYTGJWUAZPZ-WWHBDHEGSA-N 0.000 description 1
- BPFOQVIYHIFVRD-UHFFFAOYSA-N 1-decyl-1-oxidopiperidin-1-ium Chemical compound CCCCCCCCCC[N+]1([O-])CCCCC1 BPFOQVIYHIFVRD-UHFFFAOYSA-N 0.000 description 1
- PLXMOAALOJOTIY-FPTXNFDTSA-N Aesculin Natural products OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](O)[C@H]1Oc2cc3C=CC(=O)Oc3cc2O PLXMOAALOJOTIY-FPTXNFDTSA-N 0.000 description 1
- 101710088194 Dehydrogenase Proteins 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 108010041308 Endothelial Growth Factors Proteins 0.000 description 1
- 108700024394 Exon Proteins 0.000 description 1
- 101150021185 FGF gene Proteins 0.000 description 1
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 1
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 101000808011 Homo sapiens Vascular endothelial growth factor A Proteins 0.000 description 1
- 108091092195 Intron Proteins 0.000 description 1
- 108091026898 Leader sequence (mRNA) Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 101100336468 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) gem-1 gene Proteins 0.000 description 1
- 102000043276 Oncogene Human genes 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 101150062285 PGF gene Proteins 0.000 description 1
- 239000004721 Polyphenylene oxide Substances 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 208000017442 Retinal disease Diseases 0.000 description 1
- 206010038923 Retinopathy Diseases 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- 238000002105 Southern blotting Methods 0.000 description 1
- 102100031372 Thymidine phosphorylase Human genes 0.000 description 1
- 108700023160 Thymidine phosphorylases Proteins 0.000 description 1
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 1
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 1
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 1
- 102100039037 Vascular endothelial growth factor A Human genes 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- 230000019552 anatomical structure morphogenesis Effects 0.000 description 1
- 238000010804 cDNA synthesis Methods 0.000 description 1
- 229910052792 caesium Inorganic materials 0.000 description 1
- TVFDJXOCXUVLDH-UHFFFAOYSA-N caesium atom Chemical compound [Cs] TVFDJXOCXUVLDH-UHFFFAOYSA-N 0.000 description 1
- 230000033077 cellular process Effects 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 230000009920 chelation Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000035605 chemotaxis Effects 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 239000004020 conductor Substances 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 210000002969 egg yolk Anatomy 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 230000013020 embryo development Effects 0.000 description 1
- 230000009762 endothelial cell differentiation Effects 0.000 description 1
- 230000010595 endothelial cell migration Effects 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- ZJYYHGLJYGJLLN-UHFFFAOYSA-N guanidinium thiocyanate Chemical compound SC#N.NC(N)=N ZJYYHGLJYGJLLN-UHFFFAOYSA-N 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 210000003917 human chromosome Anatomy 0.000 description 1
- 210000004754 hybrid cell Anatomy 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000036046 immunoreaction Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000011278 mitosis Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 229920000570 polyether Polymers 0.000 description 1
- 238000003752 polymerase chain reaction Methods 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 230000006884 regulation of angiogenesis Effects 0.000 description 1
- 230000008844 regulatory mechanism Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 230000001177 retroviral effect Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 210000003556 vascular endothelial cell Anatomy 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/515—Angiogenesic factors; Angiogenin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Vascular Medicine (AREA)
- Immunology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
Claims (45)
- 1.以下の配列: 【配列があります】 を有し、アンギオジェネシス制御活性を有する蛋白をコードする配列を含むヌク レオチド配列。
- 2.該コードされた蛋白が交互スプライシングプロセスから由来することを特徴 とする請求項1のヌクレオチド配列。
- 3.該蛋白が位置141−142に挿入された次の21アミノ酸配列: 【配列があります】 を含む請求項2のヌクレオチド配列。
- 4.該蛋白が1以上のアミノ酸を欠失するがそのアンギオジェニック制御活性を 保持する請求項1ないし3のいずれかのヌクレオチド配列。
- 5.該蛋白がアミノ酸1からアミノ酸31まで欠失している請求項4のヌクレオ チド配列。
- 6.1以上のアミノ酸が該蛋白中で置換されているが、該蛋白はそのアンギオジ ェニック制御活性を保持している請求項1から3のいずれからヌクレオチド配列 。
- 7.請求項1ないし6のいずれかの配列のアレリックデリバティブであるヌクレ オチド配列。
- 8.請求項1ないし7のいずれかの配列に相補的なヌクレオチド配列。
- 9.同じリーディングフレームで翻訳されるヌクレオチド配列が5′又は3′位 置に共有結合的にリンクする請求項1ないし8のいずれかのヌクレオチド配列。
- 10.該リンクしたヌクレオチド配列が、該蛋白のアンギオジェネシスの制御活 性を妨害しないアミノ酸配列をコードする請求項9のヌクレオチド配列。
- 11.該リンクしたヌクレオチド配列がトキシックな活性を有する蛋白をコード する請求項9又は10のヌクレオチド配列。
- 12.配列: 【配列があります】 ここで、ヌクレオチド1からヌクレオチド321までの5′末端領域が非翻訳で あり、ヌクレオチド322からヌクレオチド768迄の領域がアンギオジェネシ ス制御活性を有する蛋白をコードし、3′末端領域が非翻訳である を含むヌクレオチド配列。
- 13.配列: 【配列があります】 の少くとも1部を含む請求項12のヌクレオチド配列。
- 14.アンギオジェネシスの制御活性を有する蛋白をコードし、1以上のヌクレ オチドを欠く請求項12又は13のヌクレオチド配列。
- 15.ヌクレオチド322からヌクレオチド414までが欠失している請求項1 4のヌクレオチド配列。
- 16.1以上のヌクレオチドが置換され、アンギオジェネシスの制御活性を有す る蛋白をコードする請求項12又は13のヌクレオチド配列。
- 17.該非翻訳5′末端が翻訳の規制領域を含む請求項12又は13のヌクレオ チド配列。
- 18.該制御領域がステムーループ二次構造を形成する請求項17のヌクレオチ ド配列。
- 19.請求項12又は13のヌクレオチド配列にアレリックなヌクレオチド配列 。
- 20.請求項12から19までのいずれかのヌクレオチド配列に相補的なヌクレ オチド配列。
- 21.アンギオジェネシスの制御活性を有する請求項1のアミノ酸配列を含む蛋 白。
- 22.該蛋白が一次トランスクリプトの交互スプライシング由来の配列を含む請 求項21の蛋白。
- 23.該配列が請求項21の配列の位置141−142に挿入され、請求項13 の配列の少くとも一部分によりコードされた配列を含む請求項22の蛋白。
- 24.該配列が請求項3の21のアミノ酸配列である請求項23の蛋白。
- 25.該蛋白が1以上のアミノ酸を欠けるが、そのアンギオジェニック制御活性 を保持する請求項21ないし24のいずれかの蛋白。
- 26.該蛋白がアミノ酸1からアミノ酸31迄を欠失している請求項25の蛋白 。
- 27.1以上のアミノ酸が該蛋白中で置換されているが、該蛋白はそのアンギオ ジェニック制御活性を保持している請求項21から24までのいずれかの蛋白。
- 28.請求項1ないし3のいずれかのヌクレオチド配列のアレリックなデリバテ ィブであるヌクレオチド配列によりコードされた蛋白。
- 29.アミノ酸鎖が末端COOH又はNH2基で共有結合的にリンクしている請 求項21から28のいずれかのアミノ酸配列を含む蛋白。
- 30.該アミノ酸鎖が蛋白それ自体のアンギオジェネシスの制御活性を妨害しな い請求項29の蛋白。
- 31.該アミノ酸鎖がトキシックな細胞活性を示す請求項29又は30の蛋白。
- 32.a)バクテリアルプラスミドのレプリケーションオリジン、b)セレクテ ィブマーカー、c)プロモーター及び該プロモーターの制御下、d)請求項1か ら20迄のいずれかのヌクレオチド配列を含むベクター。
- 33.該セレクティブマーカーが抗生物質耐性をコードする遺伝子である請求項 32のベクター。
- 34.該プロモーターが、T7ファージRNAポリメラーゼプロモーターである 請求項32又は33のいずれかのベクター。
- 35.該ベクターがプラスミドp Gem 1(Promega Corpor ation,Madison, WI,USA)を含む請求項32から34迄の いずれかのベクター。
- 36.該ベクターがプラスミドpET3(Novagen,Madison,W I USA)を含む請求項32ないし34のいずれかのベクター。
- 37.転写を制御する1以上の配列を含む請求項32ないし36のいずれかのベ クター。
- 38.該配列がトランスクリプションエンハンサーを含む請求項37のベクター 。
- 39.該配列がインデューシブルプロモーターを含む請求項37のベクター。
- 40.ポリアデニレーション部位を含む請求項32ないし40のいずれかのベク ター。
- 41.請求項32ないし40のいずれかのベクターにより形質転換された細胞。
- 42.該細胞がバクテリア細胞である請求項41の細胞。
- 43.該バクテリアがE.Coliである請求項42の細胞。
- 44.該細胞がオイカリオテック細胞である請求項41の細胞。
- 45.バクテリアカルチャーを液体培地中で、600nmで光学濃度0.35迄 生育させ、TE中に再懸濁し、遠沈しそしてリシスバッファー中に再懸濁し、細 胞を溶解することを含む方法であって、請求項41ないし43のいずれかの細胞 から請求項21ないし31のいずれかの蛋白を生産し抽出する方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IT48315A/90 | 1990-09-27 | ||
IT48315A IT1242149B (it) | 1990-09-27 | 1990-09-27 | Sequenza di nucleotidi codificante per una proteina umana con proprieta' regolative dell'angiogenesi |
PCT/IT1991/000079 WO1992006194A1 (en) | 1990-09-27 | 1991-09-26 | Nucleotide sequences coding for a human protein with angiogenesis regulative properties |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH06503225A true JPH06503225A (ja) | 1994-04-14 |
JP2987203B2 JP2987203B2 (ja) | 1999-12-06 |
Family
ID=11265849
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP3515286A Expired - Lifetime JP2987203B2 (ja) | 1990-09-27 | 1991-09-26 | アンギオジェネシス制御特性を有するヒト蛋白をコードするヌクレオチド配列 |
Country Status (10)
Country | Link |
---|---|
US (1) | US5919899A (ja) |
EP (1) | EP0550519B1 (ja) |
JP (1) | JP2987203B2 (ja) |
AT (1) | ATE173505T1 (ja) |
AU (1) | AU8635391A (ja) |
CA (1) | CA2092533C (ja) |
DE (1) | DE69130506T2 (ja) |
ES (1) | ES2127730T3 (ja) |
IT (1) | IT1242149B (ja) |
WO (1) | WO1992006194A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH06113854A (ja) * | 1991-03-28 | 1994-04-26 | Merck & Co Inc | 血管内皮細胞増殖因子cサブユニット |
Families Citing this family (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7429646B1 (en) | 1995-06-05 | 2008-09-30 | Human Genome Sciences, Inc. | Antibodies to human tumor necrosis factor receptor-like 2 |
US7964190B2 (en) | 1996-03-22 | 2011-06-21 | Human Genome Sciences, Inc. | Methods and compositions for decreasing T-cell activity |
US6635743B1 (en) | 1996-03-22 | 2003-10-21 | Human Genome Sciences, Inc. | Apoptosis inducing molecule II and methods of use |
WO1998027932A2 (en) * | 1996-12-20 | 1998-07-02 | Human Genome Sciences, Inc. | Cerebellum and embryo specific protein |
WO1998049300A2 (en) * | 1997-04-25 | 1998-11-05 | Collateral Therapeutics | Truncated vegf-related proteins |
WO2000050620A2 (en) | 1999-02-26 | 2000-08-31 | Human Genome Sciences, Inc. | Human endokine alpha and methods of use |
US20030022383A1 (en) * | 1999-04-06 | 2003-01-30 | Uab Research Foundation | Method for screening crystallization conditions in solution crystal growth |
US7727971B2 (en) * | 2000-02-04 | 2010-06-01 | Life Sciences Research Partners Vzw | Use of placental growth factor for treating ischemic muscle disease |
US7105168B1 (en) * | 2002-06-04 | 2006-09-12 | D. Collen Research Foundation Vzw | Method of improving ischemic muscle function by administering placental growth factor |
ES2484966T3 (es) | 2000-04-12 | 2014-08-12 | Novozymes Biopharma Dk A/S | Proteínas de fusión de albúmina |
DE60118186T2 (de) * | 2000-05-12 | 2006-12-28 | Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw. | Verwendung von inhibitoren des plazenta wachstumsfactors für die behandlung einer pathologischen angiogenese, pathologischen arteriogenese, entzündung, tumorbildung und/oder gefässdurchlässigkeit (ödem) |
WO2003029275A2 (en) * | 2001-10-03 | 2003-04-10 | Regeneron Pharmaceuticals, Inc. | Anti-angiogenic peptides |
WO2003060071A2 (en) | 2001-12-21 | 2003-07-24 | Human Genome Sciences, Inc. | Albumin fusion proteins |
DK1472286T3 (da) * | 2002-02-05 | 2007-08-20 | Geymonat Spa | Produktionsmetode til rekombinant placental vækstfaktor |
ITRM20020119A1 (it) * | 2002-03-05 | 2003-09-05 | Geymonat Spa | Composizioni contenenti plgf ad uso farmaceutico e cosmetico. |
ITRM20020277A1 (it) * | 2002-05-17 | 2003-11-17 | Geymonat Spa | Muteine del fattore di crescita placentare tipo 1, metodo di preparazione e loro applicazioni. |
ES2305541T3 (es) | 2002-11-16 | 2008-11-01 | Dade Behring Marburg Gmbh | Scd40l, papp-a y factor de crecimiento placentario (pigf) como combinaciones de marcadores bioquimicos en enfermedades cardiovasculares. |
WO2005087812A1 (en) * | 2004-03-05 | 2005-09-22 | Ludwig Institute For Cancer Research | Multivalent antibody materials and methods for vegf/pdgf family of growth factors |
US20060024302A1 (en) * | 2004-03-05 | 2006-02-02 | Ludwig Institute For Cancer Research | Chimeric anti-VEGF-D antibodies and humanized anti-VEGF-D antibodies and methods of using same |
CA2601267C (en) | 2005-03-24 | 2014-02-18 | Thromb-X N.V. | Novel anti-plgf antibody |
DE102005022047A1 (de) * | 2005-05-09 | 2006-11-30 | Dade Behring Marburg Gmbh | Bindungspartner des Plazentalen Wachstumsfaktors insbesondere gegen den Plazentalen Wachstumsfaktor gerichtete Antikörper, ihre Herstellung und Verwendung |
US7867490B2 (en) * | 2005-06-30 | 2011-01-11 | Vib Vzw | Treatment of liver cirrhosis and its complications |
CN101578376A (zh) * | 2005-07-13 | 2009-11-11 | 貝丝以色列女执事医疗中心 | 诊断和治疗炎性应答的方法 |
WO2007022287A2 (en) | 2005-08-15 | 2007-02-22 | Vegenics Limited | Modified vegf and pdgf with improved angiogenic properties |
ES2429225T3 (es) | 2006-05-17 | 2013-11-13 | The Ludwig Institute For Cancer Research | Anticuerpos anti VEGF-B para tratamiento o profilaxis de diabetes de tipo II o síndrome metabólico |
EP2237792B1 (en) | 2007-12-26 | 2017-05-24 | Vaccinex, Inc. | Anti-c35 antibody combination therapies and methods |
EP2238448B1 (en) | 2008-01-07 | 2016-04-06 | Ortho-Clinical Diagnostics, Inc. | Calibrator/control for simultaneous assay of proteins capable of complexing with one another |
US20100004306A1 (en) * | 2008-06-18 | 2010-01-07 | Abbott Laboratories | PIGF-1 Assay and kits and components thereof |
US8741287B2 (en) * | 2008-06-18 | 2014-06-03 | Abbott Laboratories | PlGF-1 assay and kits and components thereof |
CN102239178B (zh) | 2008-10-02 | 2017-06-23 | Vib研究所 | 抑制PlGF以治疗费城染色体阳性白血病 |
EP2295449A1 (en) | 2009-09-09 | 2011-03-16 | Dompe PHA.R.MA S.p.A. | PLGF-1 in homodimeric form |
CN103087153B (zh) * | 2011-10-28 | 2015-05-06 | 上海市第一人民医院 | 一类新的抑制新生血管的小肽及其应用 |
ES2628321T3 (es) | 2011-12-01 | 2017-08-02 | Thrombogenics N.V. | Mejora del resultado de una trabeculectomía |
WO2014055849A1 (en) | 2012-10-05 | 2014-04-10 | Alere San Diego, Inc. | Methods for diagnosing and prognosing placental dysfunction and pre-eclampsia |
-
1990
- 1990-09-27 IT IT48315A patent/IT1242149B/it active IP Right Grant
-
1991
- 1991-09-26 CA CA002092533A patent/CA2092533C/en not_active Expired - Lifetime
- 1991-09-26 DE DE69130506T patent/DE69130506T2/de not_active Expired - Lifetime
- 1991-09-26 US US08/039,297 patent/US5919899A/en not_active Expired - Lifetime
- 1991-09-26 EP EP91916657A patent/EP0550519B1/en not_active Expired - Lifetime
- 1991-09-26 AU AU86353/91A patent/AU8635391A/en not_active Abandoned
- 1991-09-26 JP JP3515286A patent/JP2987203B2/ja not_active Expired - Lifetime
- 1991-09-26 AT AT91916657T patent/ATE173505T1/de not_active IP Right Cessation
- 1991-09-26 WO PCT/IT1991/000079 patent/WO1992006194A1/en active IP Right Grant
- 1991-09-26 ES ES91916657T patent/ES2127730T3/es not_active Expired - Lifetime
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH06113854A (ja) * | 1991-03-28 | 1994-04-26 | Merck & Co Inc | 血管内皮細胞増殖因子cサブユニット |
Also Published As
Publication number | Publication date |
---|---|
AU8635391A (en) | 1992-04-28 |
US5919899A (en) | 1999-07-06 |
IT9048315A0 (it) | 1990-09-27 |
ATE173505T1 (de) | 1998-12-15 |
IT1242149B (it) | 1994-02-16 |
CA2092533A1 (en) | 1992-03-28 |
JP2987203B2 (ja) | 1999-12-06 |
CA2092533C (en) | 2002-05-28 |
DE69130506D1 (de) | 1998-12-24 |
ES2127730T3 (es) | 1999-05-01 |
EP0550519B1 (en) | 1998-11-18 |
WO1992006194A1 (en) | 1992-04-16 |
DE69130506T2 (de) | 1999-06-24 |
EP0550519A1 (en) | 1993-07-14 |
IT9048315A1 (it) | 1992-03-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JPH06503225A (ja) | アンギオジェネシス制御特性を有するヒト蛋白をコードするヌクレオチド配列 | |
US5607918A (en) | Vascular endothelial growth factor-B and DNA coding therefor | |
JP3802292B2 (ja) | 上皮細胞に特異的な成長因子をコードするdna | |
US6689580B1 (en) | Growth factor | |
RU2265661C2 (ru) | Слитый полипептид, способный связываться с полипептидом vegf, и кодирующая его молекула нуклеиновой кислоты, их получение и применение | |
PT93996B (pt) | Processo para a producao de factor de crescimento de celulas endoteliais vasculares e de dna codificador do mesmo | |
JPS63502725A (ja) | 組換えヒト内皮細胞成長因子 | |
EA005581B1 (ru) | ПОЛИПЕПТИДЫ ЦИТОКИНА Zcyto10 ЧЕЛОВЕКА И МЫШИ, КОДИРУЮЩИЕ ИХ ПОЛИНУКЛЕОТИДЫ И АНТИТЕЛА К УКАЗАННЫМ ПОЛИПЕПТИДАМ | |
JP2010029207A (ja) | HMG蛋白質(highmobilitygroupprotein)遺伝子の核酸配列およびそれらの使用 | |
JP4493854B2 (ja) | リガンドの生物学的活性を増強する方法 | |
JP2002526073A (ja) | 新規のヒト生長分化因子のコード配列、そのdna配列によりコードされるポリペプチド、およびこれらの製造方法。 | |
US5708156A (en) | Epidermal growth factor receptor-like gene product and its uses | |
JPH02288897A (ja) | 内皮細胞増殖因子 | |
Yasuhisa et al. | Isolation of the cDNA clone for mouse glycophorin, erythroid-specific membrane protein | |
CN100431611C (zh) | 多肽-脂质体与人血管内皮生长因子基因重组质粒复合物及用途 | |
US6699968B1 (en) | Construction and use of synthetic constructs encoding syndecan | |
JPH0965885A (ja) | エピモルフィン改変体 | |
JPH05507844A (ja) | 修飾したヘパリン結合増殖因子 | |
JPH05219959A (ja) | 新規なdnaおよびそれによってコードされる蛋白質 | |
JPH02291268A (ja) | ヒトリンホトキシンn末端欠失変異体 | |
JP2003169683A (ja) | 新規脱共役蛋白質mt0029 | |
JPH0556781A (ja) | 発現用プロモーターおよびその用途 | |
JPH02307000A (ja) | ヒトカルパスタチン様ポリペプチド |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20081001 Year of fee payment: 9 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20091001 Year of fee payment: 10 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20101001 Year of fee payment: 11 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20111001 Year of fee payment: 12 |
|
EXPY | Cancellation because of completion of term |